Comparison of Topical Tofacitinib and 0.1% Hypochlorous Acid in a Murine Atopic Dermatitis Model
Open accessAbstract
BACKGROUND: Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor tofacitinib, both of which are currently in clinical phase studies for treatment of human atopic dermatitis. METHODS: The effect of topically administered HOCl (0.1%) in gel was compared to a topical formulation of tofacitinib (0.5%) in a therapeutic setting on atopic dermatitis-like lesions in NC/Nga mice as well as itch behaviour. NC/Nga mice were sensitized with house dust mite allergen. After reaching visible lesions, mice were treated either topically with HOCl or tofacitinib or gel vehicle for 17 days. After termination of the study, dorsal root ganglia were isolated for ex vivo stimulation and skin samples were taken for cytokine determination in inflamed skin. RESULTS: When administered onto lesional skin of NC/Nga mice, both HOCl and tofacitinib reduced lesions and scratching behaviour. The reduced inflammatory response by HOCl and tofacitinib treatment was demonstrated by diminished inflammatory cytokines in affected skin tissue from NC/Nga mice. Dorsal root ganglia neurons re-stimulated with a range of mediators of itch showed a reduced response compared to the vehicle control mice, when isolated from tofacitinib or HOCl treated mice. CONCLUSIONS: These data indicate a similar beneficial potential of topical high dose PR022 HOCl (0.1%) in gel and tofacitinib, in a translational murine model of atopic dermatitis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HOCl-based therapeutics optimized for topical delivery are now serving as pharmaceutical formulations for wound management, scar prevention, diabetic ulcers, atopic dermatitis, pruritus, psoriasis, and seborrheic dermatitis.
“Importantly, HOCl-based therapeutics optimized for topical delivery are now serving as pharmaceutical formulations for wound management, scar prevention, diabetic ulcers, atopic dermatitis, pruritus, psoriasis, and seborrheic dermatitis (84, 168, 173, 174).”
From Hypochlorous Acid: From Innate Immune Factor and Environmental Toxicant to Chemopreventive Agent Targeting Solar UV-Induced Skin Cancer (2022) · cites this paper as [173]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Williams, H. C., Leung, D. Y. M., Thestrup‐Pedersen, K., & David, T. J. (2000) · Cited by 4,597 · see citing works
Leung, D. Y. M., & Bieber, T. R. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12193-9 · Cited by 1,149 · see citing works
The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch
Wilson, S. R., Thé, L., Batia, L. M., Beattie, K., Katibah, G. E., McClain, S. P., Pellegrino, M., Estandian, D., & Bautista, D. M. (2013) · Cell · doi:10.1016/j.cell.2013.08.057 · Cited by 989 · see citing works
Akdiş, C. A., Akdiş, M., Bieber, T. R. M., Bindslev‐Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q. A., Kapp, A., Leung, D. Y. M., Lipozenčić, J., et al. (2006) · Allergy · doi:10.1111/j.1398-9995.2006.01153.x · Cited by 732 · see citing works
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J., Biedermann, T., Eyerich, K., Gilles, S., Guttman‐Yassky, E., Hoetzenecker, W., Knol, E. F., Simon, H., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 593 · see citing works
Akdis, C. A., Akdis, M., Bieber, T., Bindslev-Jensen, C., Boguniewicz, M., Eigenmann, P., Hamid, Q., Kapp, A., Leung, D. Y. M., Lipozencic, J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.03.045 · Cited by 460 · see citing works
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Bissonnette, R., Papp, K. A., Poulin, Y. P., Gooderham, M., Raman, M., Mallbris, L., Wang, C., Purohit, V. S., Mamolo, C. M., Papacharalambous, J., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14871 · Cited by 420 · see citing works
Atopic dermatitis: A practice parameter update 2012
Schneider, L. C., Tilles, S. A., Lio, P., Boguniewicz, M., Beck, L. A., LeBovidge, J., Novak, N., Bernstein, D., Blessing-Moore, J., Khan, D. A., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.672 · Cited by 417 · see citing works
Sensory neurons and circuits mediating itch
LaMotte, R. H., Dong, X., & Ringkamp, M. (2013) · Nature reviews. Neuroscience · doi:10.1038/nrn3641 · Cited by 299 · see citing works
Histamine H1, H3 and H4 receptors are involved in pruritus
Roßbach, K., Nassenstein, C., Gschwandtner, M., Schnell, D., Sander, K., Seifert, R., Stark, H., Kietzmann, M., & Bäumer, W. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.002 · Cited by 154 · see citing works
Self-citationFukuyama, T., Ehling, S., Cook, E. H., & Bäumer, W. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.223784 · Cited by 101 · see citing works
Self-citationHypochlorous acid is antipruritic and anti‐inflammatory in a mouse model of atopic dermatitis
Fukuyama, T., Martel, B. C., Linder, K. E., Ehling, S., Ganchingco, J. R. C., & Bäumer, W. (2017) · Clinical & Experimental Allergy · doi:10.1111/cea.13045 · Cited by 74 · see citing works
Self-citationTranslational Animal Models of Atopic Dermatitis for Preclinical Studies.
Martel, B. C., Lovato, P., Bäumer, W., & Olivry, T. (2017) · Europe PMC (PubMed Central) · Cited by 74 · see citing works
Self-citationFukuyama, T., Ganchingco, J. R. C., Mishra, S. K., Olivry, T., Rzagalinski, I., Volmer, D. A., & Bäumer, W. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.12.960 · Cited by 48 · see citing works
Self-citationLim, S. J., Kim, M., Randy, A., Nam, E. J., & Nho, C. W. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12640 · Cited by 40 · see citing works
Bäumer, W., Gorr, G., Hoppmann, J., Ehinger, A. M., Rundfeldt, C., & Kietzmann, M. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021585 · Cited by 24 · see citing works
Self-citationAntipruritic hydrogel for the treatment of atopic dermatitis: an open-label pilot study.
Draelos, Z. D. (2012) · PubMed · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics
Bai, R., Zheng, Y., & Dai, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00313-3 · Cited by 46 · see citing works
Temperature-triggered in situ forming lipid mesophase gel for local treatment of ulcerative colitis
Carone, M., Spalinger, M. R., Gaultney, R. A., Mezzenga, R., Hlavačková, K., Mookhoek, A., Krebs, P., Rogler, G., Luciani, P., & Aleandri, S. (2023) · Nature Communications · doi:10.1038/s41467-023-39013-3 · Cited by 38 · see citing works
Snell, J. A., Jandova, J., & Wondrak, G. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.887220 · Cited by 37 · see citing works
Inhibitory effect of Carnosol on UVB-induced inflammation via inhibition of STAT3
Yeo, I. J., Park, J. H., Jang, J. S., Lee, D., Park, J. E., Choi, Y., Joo, J. H., Song, J. K., Jeon, H. O., & Hong, J. T. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-018-1088-1 · Cited by 35 · see citing works
Kishimoto, R., Kato, N., Koike, M., Iwashita, N., Takagi, Y., & Fukuyama, T. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153679 · Cited by 25 · see citing works
Self-citationRuxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
Scuron, M., Fay, B., Connell, A. J., Peel, M. T., & Smith, P. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.620098 · Cited by 20 · see citing works
Translational Relevance of Mouse Models of Atopic Dermatitis
Choi, J., Sutaria, N. H., Roh, Y. S., Bordeaux, Z. A., Alphonse, M. P., Kwatra, S. G., & Kwatra, M. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040613 · Cited by 18 · see citing works
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis
Fardos, M., Singh, R., Perche, P., Kelly, K., & Feldman, S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.1993061 · Cited by 11 · see citing works
Kaneki, M., Ohira, C., Takahashi, M., Iwashita, N., Takagi, Y., Nagane, M., Uchiyama, J., & Fukuyama, T. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110920 · Cited by 14 · see citing works
Self-citationModifications of IL-6 by Hypochlorous Acids: Effects on Receptor Binding
Robins, L. I., Keim, E. K., Robins, D. B., Edgar, J. S., Meschke, J. S., Gafken, P. R., & Williams, J. F. (2021) · ACS Omega · doi:10.1021/acsomega.1c05297 · Cited by 12 · see citing works
Lio, P. (2019) · Journal of Dermatology & Cosmetology · doi:10.15406/jdc.2019.03.00109 · Cited by 6 · see citing works
LEKTI domain 6 displays anti-inflammatory action in vitro and in a murine atopic dermatitis model
Canbolat, P., Wilzopolski, J., Kaessmeyer, S., Filor, V., Vidak, J., Rüger, M., Mägert, H., Forssmann, W., & Bäumer, W. (2024) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2024.03.004 · Cited by 2 · see citing works
Self-citationSaito, H., Usui, C., Matsuzaka, R., Ohira, C., Kaneki, M., Takagi, Y., Hoshino, Y., & Fukuyama, T. (2026) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.26-41 · Cited by 1 · see citing works
Self-citationOhira, C., Komai, N., Inaba, Y., Hamauzu, A., Kaneki, M., Nagane, M., Nakamura, M., Miyasato, K., Nagahara, Y., Kai, H., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116812 · Cited by 1 · see citing works
Self-citationRobins, L. I., Keim, E. K., Robins, D. B., Edgar, S., Meschke, J. S., Gafken, P. R., & Williams, J. F. (2021) · doi:10.33774/chemrxiv-2021-s68cw · Cited by 1 · see citing works
Treatment of Meibomian Gland Disease
Tauber, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-82753-9.00004-7
Kato, K., Akamatsu, M., Kakimaru, S., Koreishi, M., Takagi, M., Miyashita, M., Murata, Y., Nakamura, Y., Satoh, A., & Tsujino, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3852180/v1
- Authors
- Fukuyama, T., Ehling, S., Wilzopolski, J., & Bäumer, W.
- Affiliations
- North Carolina State University (US)
- Corresponding author
- Bäumer, Wolfgang
- Venue
- BMC Pharmacology and Toxicology
- Published
- 2018-07-03
- Volume
- 19
- Issue
- 1
- Pages
- 37-37
- ISSN
- 2050-6511 (ISSN-L)
- PMC
- PMC6029395
- OpenAlex
- W2810720197
- Cited by
- 17
- References
- 17
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 6 · 2019: 1 · 2018: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Pharmacology and Toxicology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
- Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
- Funders
- Realm Therapeutics
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, hypochlorous acid, tofacitinib, topical treatment, JAK inhibitors, NC/Nga mice, house dust mite sensitization, dorsal root ganglia, inflammatory cytokines, skin inflammation
- MeSH terms
- Administration, Topical, Animals, Cells, Cultured, Dermatitis, Atopic, Disease Models, Animal, Female, Ganglia, Spinal, Hypochlorous Acid, Immunoglobulin E, Neurons, Piperidines, Pyrimidines, Pyrroles, Skin, Cytokines, Protein Kinase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
